In The News

A Risky Business Model in China Costs Cardinal Health $8.8M

Anti-Corruption Report

18 Mar 2020

James Koukios spoke to Anti-Corruption Report for an article that covers how Cardinal Health’s SEC settlement that cost them $8.8 million due to its Chinese subsidiary violating the FCPA’s internal controls and recordkeeping provisions.

“The [cease-and-desist] order suggests to me that Cardinal Health was pretty thoughtful in how it approached these issues,” James said, adding that the termination of most of the other marketing accounts “suggests that Cardinal may have done at least some pre- and post-acquisition due diligence and integration work that resulted in red flags for other arrangements but provided some confidence that this arrangement could go forward.”

Read the full article (subscription required).



Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.